Literature DB >> 31656636

Patient selection in sepsis: precision medicine using phenotypes and its implications for future clinical trial design.

Daisuke Hasegawa1, Osamu Nishida1.   

Abstract

Entities:  

Year:  2019        PMID: 31656636      PMCID: PMC6790464          DOI: 10.21037/jtd.2019.09.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

1.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.

Authors:  Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay
Journal:  Lancet Respir Med       Date:  2014-05-19       Impact factor: 30.700

3.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

4.  Albumin replacement in patients with severe sepsis or septic shock.

Authors:  Pietro Caironi; Gianni Tognoni; Serge Masson; Roberto Fumagalli; Antonio Pesenti; Marilena Romero; Caterina Fanizza; Luisa Caspani; Stefano Faenza; Giacomo Grasselli; Gaetano Iapichino; Massimo Antonelli; Vieri Parrini; Gilberto Fiore; Roberto Latini; Luciano Gattinoni
Journal:  N Engl J Med       Date:  2014-03-18       Impact factor: 91.245

Review 5.  The definition of acute kidney injury and its use in practice.

Authors:  Mark E Thomas; Caroline Blaine; Anne Dawnay; Mark A J Devonald; Saoussen Ftouh; Chris Laing; Susan Latchem; Andrew Lewington; David V Milford; Marlies Ostermann
Journal:  Kidney Int       Date:  2014-10-15       Impact factor: 10.612

6.  Improved survival in critically ill patients: are large RCTs more useful than personalized medicine? No.

Authors:  Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2016-09-12       Impact factor: 17.440

7.  Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.

Authors:  Christopher W Seymour; Jason N Kennedy; Shu Wang; Chung-Chou H Chang; Corrine F Elliott; Zhongying Xu; Scott Berry; Gilles Clermont; Gregory Cooper; Hernando Gomez; David T Huang; John A Kellum; Qi Mi; Steven M Opal; Victor Talisa; Tom van der Poll; Shyam Visweswaran; Yoram Vodovotz; Jeremy C Weiss; Donald M Yealy; Sachin Yende; Derek C Angus
Journal:  JAMA       Date:  2019-05-28       Impact factor: 56.272

8.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

9.  Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Authors:  J Kienast; M Juers; C J Wiedermann; J N Hoffmann; H Ostermann; R Strauss; H-O Keinecke; B L Warren; S M Opal
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

10.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.